AdityaH.GaurMD
Pediatric Infectious Disease • Memphis, TNAssociate Professor, Preventive Medicine, University of Tennessee Health Science Center College of Medicine
Are you Dr. Gaur?
Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.
- Connect with colleagues in the same hospital or clinic
You already have 41 invites waiting! - Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
262 Danny Thomas Pl
Memphis, TN 38105Phone+1 888-226-4343- Is this information wrong?
Summary
- Dr. Aditya Gaur, MD is a pediatric infectious disease specialist in Memphis, Tennessee. He is currently licensed to practice medicine in Tennessee and Pennsylvania. He is affiliated with St. Jude Children's Research Hospital and is an Associate Professor at University of Tennessee Health Science Center College of Medicine.
Education & Training
University of TennesseeFellowship, Pediatric Infectious Diseases, 1999 - 2003
Geisinger Health SystemResidency, Pediatrics, 1996 - 1999
Government Medical College GujuratClass of 1994
Certifications & Licensure
TN State Medical License 2004 - 2024
PA State Medical License 1999 - 2004- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Infectious Diseases
Clinical Trials
- Directly Observed Therapy for HIV Infected Adolescents Start of enrollment: 2006 Apr 01
- Project ACCEPT: Engaging Newly Diagnosed HIV+ Youth in Care Start of enrollment: 2013 Jan 01
- Two Part Study to Evaluate Pharmacokinetics, Safety, and Antiviral Activity of Elvitegravir Administered With a PI/r Background Regimen for ARV Treatment-Experienced Pediatric Participants Start of enrollment: 2013 Aug 26
- Join now to see all
Publications & Presentations
PubMed
- Pharmacokinetics and safety of coformulated bictegravir, emtricitabine, and tenofovir alafenamide in children aged 2 years and older with virologically suppressed HIV:...Carina A Rodriguez, Eva Natukunda, Renate Strehlau, Esme L Venter, Supattra Rungmaitree, Coleen K Cunningham, Umesh Lalloo, Pope Kosalaraksa, Elizabeth HellstrÖm, Afaa...> ;The Lancet. HIV. 2024 Apr 12
- Safety and pharmacokinetics of oral and long-acting injectable cabotegravir or long-acting injectable rilpivirine in virologically suppressed adolescents with HIV (IMP...Aditya H Gaur, Edmund V Capparelli, Katherine Calabrese, Kristin Baltrusaitis, Mark A Marzinke, Cynthia McCoig, Rodica M Van Solingen-Ristea, Sisinyana Ruth Mathiba, A...> ;The Lancet. HIV. 2024 Apr 1
- Acceptability and tolerability of long-acting injectable cabotegravir or rilpivirine in the first cohort of virologically suppressed adolescents living with HIV (IMPAA...Elizabeth D Lowenthal, Jennifer Chapman, Rachel Ohrenschall, Katherine Calabrese, Kristin Baltrusaitis, Barbara Heckman, Dwight E Yin, Allison L Agwu, Conn Harrington,...> ;The Lancet. HIV. 2024 Apr 1
- Join now to see all
Press Mentions
Here’s What We Know About the Johnson & Johnson VaccineFebruary 25th, 2021- Johnson & Johnson Covid-19 Vaccine Is Safe and Effective, FDA Analysis FindsFebruary 24th, 2021
- COVID-19 Vaccine Trial Happening in Memphis Still Needs More ParticipantsDecember 4th, 2020
- Join now to see all
Hospital Affiliations
St. Jude Children's Research HospitalMemphis, Tennessee
